Amount awarded from CPRIT grant.

No definition available.

Name:	nhwk_AmountAwardedFromCpritGrant
Namespace Prefix:	nhwk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount the company is required to match of each dollar of grant.

+ References

No definition available.

+ Details

Name:	nhwk_AmountOfMatchForEveryDollarOfGrant
Namespace Prefix:	nhwk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The contract amount retained.

+ References

No definition available.

+ Details

Name:	nhwk_ContractAmountRetained
Namespace Prefix:	nhwk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of Contribution to be made in matching funds over the life of a project.

+ References

No definition available.

+ Details

Name:	nhwk_CpritFundingPlanEmployerMatchingContributionsTotalAmount
Namespace Prefix:	nhwk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of cash paid to seller of discontinued operation

+ References

No definition available.

+ Details

Name:	nhwk_DisposalGroupIncludingDiscontinuedOperationAmountPaidToSeller
Namespace Prefix:	nhwk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License costs.

+ References

No definition available.

+ Details

Name:	nhwk_LicenseCost
Namespace Prefix:	nhwk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

N/A

+ References

No definition available.

+ Details

Name:	nhwk_LicenseRevenueAbstract
Namespace Prefix:	nhwk_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of revenue received as milestone payments.

+ References

No definition available.

+ Details

Name:	nhwk_LicenseRevenueMilestonePaymentsReceived
Namespace Prefix:	nhwk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the number of customers revenue was derived from.

+ References

No definition available.

+ Details

Name:	nhwk_NumberOfCustomersRevenueDerivedFrom
Namespace Prefix:	nhwk_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of vials for which manufacturing conversion is completed.

+ References

No definition available.

+ Details

Name:	nhwk_NumberOfVialsManufacturingConversionCompleted
Namespace Prefix:	nhwk_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

The number of vials to be delivered.

+ References

No definition available.

+ Details

Name:	nhwk_NumberOfVialsToBeDelivered
Namespace Prefix:	nhwk_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of process development contract liability.

+ References

No definition available.

+ Details

Name:	nhwk_ProcessDevelopmentContractLiability
Namespace Prefix:	nhwk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of process development contract liability net changes to contract balance recognized since beginning of period due to amounts collected.

+ References

No definition available.

+ Details

Name:	nhwk_ProcessDevelopmentContractLiabilityNetChangeToContractBalance
Namespace Prefix:	nhwk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of process development contract liability reclassified to revenue as a result of performance obligations satisfied.

+ References

No definition available.

+ Details

Name:	nhwk_ProcessDevelopmentContractLiabilityReclassificationToRevenue
Namespace Prefix:	nhwk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

N/A

+ References

No definition available.

+ Details

Name:	nhwk_ProcessDevelopmentRevenueAbstract
Namespace Prefix:	nhwk_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of process development revenue recognized.

+ References

No definition available.

+ Details

Name:	nhwk_ProcessDevelopmentRevenueRecognized
Namespace Prefix:	nhwk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Royalty percentage after threshold is met.

+ References

No definition available.

+ Details

Name:	nhwk_RoyaltyPercentageAfterThresholdIsMet
Namespace Prefix:	nhwk_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Threshold amount for match of grant.

+ References

No definition available.

+ Details

Name:	nhwk_ThresholdAmountForMatchOfGrant
Namespace Prefix:	nhwk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481990/310-10-45-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481990/310-10-45-9

+ Details

Name:	us-gaap_AccountsReceivableNetCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-21

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-20

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-18

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-20

+ Details

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-8

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479837/606-10-45-4

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479837/606-10-45-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-8

+ Details

Name:	us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_DeferredRevenueArrangementLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B

+ Details

Name:	us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-SubTopic 10
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-13

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=nhwk_ElusysTherapeuticsIncBusinessMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_MajorCustomersAxis=nhwk_OneCustomerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_MajorCustomersAxis=nhwk_TwoCustomersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=nhwk_ShattuckLabsIncShattuckMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=nhwk_AnthimVialsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BalanceSheetLocationAxis=nhwk_AccountsReceivableCurrentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=nhwk_PelicanTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_GrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TransactionTypeAxis=nhwk_TrancheOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TransactionTypeAxis=nhwk_TrancheTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TransactionTypeAxis=nhwk_TrancheThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Revenue (Details)				1 Months Ended						12 Months Ended
Revenue (Details)	Sep. 13, 2023 USD ($) item	Sep. 13, 2022 USD ($)	Apr. 19, 2022 USD ($) item	Apr. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2019 USD ($)	Oct. 31, 2017 USD ($)	May 31, 2017 USD ($)	Jun. 30, 2016 USD ($)	Dec. 31, 2023 USD ($) customer	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Grant Revenue
Revenue										$ 6,994,838	$ 370,176
Process Development Revenue
Process development revenue recognized										6,600,000	100,000
Process development contract liabilities, beginning of period										1,618,308	37,500
Reclassification to revenue as the result of performance obligations satisfied										(6,358,617)	(76,019)
Net change to contract balance recognized since beginning of period due to amounts collected										7,129,750	1,656,827
Process development contract liabilities, end of period										2,389,441	1,618,308
Recognized revenue										1,200,000	3,000.000
Accounts receivable										375,192	81,456	$ 66,049
Elusys Therapeutics business unit
Grant Revenue
Revenue										$ 6,699,200	$ 6,012,993
One customer
Process Development Revenue
Number of customers process development revenue was derived from \| customer										1
Two customers
Process Development Revenue
Number of customers process development revenue was derived from \| customer										2
Sales revenue net \| Customer Concentration Risk \| One customer
Grant Revenue
Concentration risk, percentage										74.00%
Sales revenue net \| Customer Concentration Risk \| Two customers
Grant Revenue
Concentration risk, percentage										86.00%
Shattuck
License Revenue
License fee received									$ 50,000
Proceeds from milestone payment					$ 100,000
ANTHIM Vials
Grant Revenue
Number of vials to be delivered \| item			3,000
Contract award			$ 5,900,000
Number of vials, manufacturing conversion \| item	23,732
Revenue	$ 6,700,000
ANTHIM Vials \| Elusys Therapeutics business unit
Grant Revenue
Contract amount retained		$ 1,100,000
Disposal group including discontinued operation Amount paid to seller		4,600,000
ANTHIM Vials \| Accounts receivable
Grant Revenue
Contract with customer, receivable, after allowance for credit loss, current		$ 5,900,000
Pelican Therapeutics, Inc. \| Grant and contract revenue
Grant Revenue
Revenue				$ 1,500,000						$ 15,200,000
Amount the company is required to match of each dollar of grant										0.50
Threshold amount for match of grant										1.00
Contribution to be made by Pelican										$ 7,600,000
Pelican Therapeutics, Inc. \| Grant and contract revenue \| Maximum
Grant Revenue
Amount awarded from CPRIT grant									$ 15,200,000
Royalty percentage after threshold is met										1.00%
Pelican Therapeutics, Inc. \| Grant and contract revenue \| Tranche 1
Grant Revenue
Revenue								$ 1,800,000
Pelican Therapeutics, Inc. \| Grant and contract revenue \| Tranche 2
Grant Revenue
Revenue							$ 6,500,000
Pelican Therapeutics, Inc. \| Grant and contract revenue \| Tranche 3
Grant Revenue
Revenue						$ 5,400,000